Faeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The company is developing the regimen in endometrial cancer and hormone receptor-positive, HER2-negative
